A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia
Latest Information Update: 13 Jan 2026
At a glance
- Drugs DISC 0974 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Disc Medicine
Most Recent Events
- 18 Dec 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Jan 2026.
- 17 Oct 2025 According to a Disc Medicine media release, updated data from this study will be presented as a poster presentation at the upcoming 2025 American Society of Nephrology (ASN) Kidney Week, which will be held in Houston, TX on November 6-9, 2025.
- 19 Aug 2025 Status changed from recruiting to active, no longer recruiting.